The Peptide NewsroomPeptide research, industry and supply-chain headlines

GLP-1 Drugs May Influence Brain Function, But Semaglutide Failed in Alzheimer's Trials

Topic card: glp-1

A new review by researchers at the University of Gothenburg and the University of Copenhagen, written at the invitation of the journal Science, examines whether GLP-1 medications used for obesity and type 2 diabetes also affect memory and thinking.

The drugs in question are semaglutide (sold as Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound). Beyond weight loss and blood sugar control, the authors write, these medications influence biological processes involved in brain function, which is why the cognitive question keeps coming up.

Where the human data splits

Animal studies suggest GLP-1 medications can influence learning and memory. Human research has been less consistent: analyses of patient health records have found an association between GLP-1 treatment and a reduced risk of dementia in people with type 2 diabetes, but the authors are clear that observational findings cannot establish whether the drugs are responsible.

That is the honest version of a claim the supplement and telehealth marketing world has already run far ahead with. An association in a records database is a reason to run a trial, not a reason to sell one.

The Alzheimer's result

The trial evidence has been blunt. In Novo Nordisk's EVOKE and EVOKE+ trials, semaglutide failed to slow progression of early Alzheimer's disease, and while the treatment affected several biological markers associated with the condition, those changes did not translate into measurable slowing of the disease.

Who might still benefit

The reviewers argue the Alzheimer's failure does not close the question. People living with obesity or type 2 diabetes sometimes have difficulty with attention, planning and processing speed, problems often associated with metabolic health and blood vessel function rather than neurodegeneration, and the authors suggest those may respond differently to treatment.

First author Stina Borchers says the field needs to find out whether treatment can help people with obesity or diabetes preserve cognitive abilities, particularly if it begins before cognitive problems become established, and which patients might benefit. Senior author Christoffer Clemmensen frames increasingly sophisticated obesity drugs as a tool for separating direct brain effects from indirect metabolic ones.

The muscle mass caveat

The authors stress that treatment carries potential drawbacks, particularly for older adults and physically frail people. Rapid weight loss can reduce muscle mass, which may weaken physical function and offset some possible benefits.

Bottom line

The review calls for clinical trials that measure memory, attention and other cognitive abilities from the moment patients start treatment, tracked over time. Whether GLP-1 drugs genuinely protect brain function, and in whom, remains unsettled.

Source: RSS.app — Renewal bundle. Read the original.

Filed under: glp-1, safety

Comments (0)

Discussion happens on Reddit.
Questions and corrections go to r/PeptideNewsroom.

Go to r/PeptideNewsroom

Corrections are the most useful thing you can post. Comments touching dosing, sourcing or links are held for a moderator first.

More from The Peptide Newsroom

Karnataka Regulators Cancel a Bengaluru Peptide Party as India's Longevity Market Accelerates

Karnataka's drug regulator canceled a Bengaluru "Peptide Party" on August 29 and questioned the organizers about ingredients, legality and health claims. The Indian Express reports the shutdown against a biohacking market Grand View Research valued at $1.21 billion in 2025.

What the Research Actually Says About Semaglutide, From Weight Loss to Memory

Semaglutide has large human trials behind its weight and metabolic outcomes, but the newer questions about energy expenditure, muscle preservation and cognition are far less settled. A digest of what researchers have actually reported, and where the evidence stops.

Kemin Pitches Positive Aging, GLP-1 Support and Gut Health as Its 2027 Trends

Kemin's Filipa Quintela told Nutritional Outlook at SupplySide Global that positive aging, GLP-1 support through Slendesta, and gut health via the Gutopia platform will shape the supplier's 2027 development. She also put American lutein intake at around 2 mg a day against an optimal 10 mg.